^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BCL2 fusion

    i
    Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
    Entrez ID:
    596
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    28d
    Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively. (PubMed, Leuk Lymphoma)
    The former is considered to be mediated by VDJ-recombination, while the latter by the class switch recombination process. There were no particular features in FL or CLL cases with IGH::5' BCL2 breakpoints compared with those with t(14;18)(q32;q21)/IGH::BCL2 involving the 3' breakpoint cluster regions.
    Journal
    |
    BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 fusion
    1year
    Diagnostic clues of BCL2-negative, faint, or controversial follicular lymphomas: A study of 103 cases. (PubMed, Hum Pathol)
    In conclusion, morphological examination of the distribution of CD20-and/or CD10-positive cells and the presence of diffuse area could be used to diagnose FL in most cases. The majority of the remaining FL cases could be diagnosed using other BCL2 clones and clonality analyses.
    Retrospective data • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive • BCL2 positive • BCL2 fusion
    1year
    Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. (PubMed, Signal Transduct Target Ther)
    Genetic subtype-guided targeted agents achieved encouraging clinical response when combined with immunochemotherapy. Collectively, LymphPlex provided high efficacy and feasibility, representing a step forward to the mechanism-based targeted therapy in DLBCL.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • B2M (Beta-2-microglobulin) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD70 (CD70 Molecule) • EP300 (E1A binding protein p300) • TNFAIP3 (TNF Alpha Induced Protein 3) • GNA13 (G Protein Subunit Alpha 13) • IRF8 (Interferon Regulatory Factor 8) • PIM1 (Pim-1 Proto-Oncogene) • TNFRSF14 (TNF Receptor Superfamily Member 14) • CCND3 (Cyclin D3) • IRF4 (Interferon regulatory factor 4) • SOCS1 (Suppressor Of Cytokine Signaling 1) • PRDM1 (PR/SET Domain 1) • STAT6 (Signal transducer and activator of transcription 6) • TNFRSF18 (TNF Receptor Superfamily Member 18) • BTG2 (BTG Anti-Proliferation Factor 2) • DDX3X (DEAD-Box Helicase 3 X-Linked) • TBL1XR1 (TBL1X Receptor 1) • ZFP36 (ZFP36 Ring Finger Protein)
    |
    TP53 mutation • ARID1A mutation • NOTCH1 mutation • EZH2 mutation • MYC expression • MYC rearrangement • STAT3 mutation • GNA13 mutation • PRDM1 mutation • IRF8 mutation • BCL2 fusion • BCL6 fusion
    1year
    Follicular Lymphoma in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms-Updated Classification and New Biological Data. (PubMed, Cancers (Basel))
    In-situ follicular B-cell neoplasm, pediatric-type FL, duodenal-type FL and primary cutaneous follicle center lymphoma are categorized as discrete entities. In addition, novel findings concerning underlying biological mechanisms in the pathogenesis of early and systemic follicular lymphoma will be presented.
    Review • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • TNFRSF14 (TNF Receptor Superfamily Member 14) • STAT6 (Signal transducer and activator of transcription 6) • TNFRSF18 (TNF Receptor Superfamily Member 18) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    BCL2 expression • TNFRSF14 mutation • BCL2 fusion
    over1year
    IGH/BCL2 Status Better Predicts Clinico-Pathological Behavior in Primary Splenic Follicular Lymphoma than Histological Grade and Other Molecular Markers. (PubMed, Clin Pathol)
    This profile is associated with less aggressive clinical behavior even when histopathology represents a high-grade pattern. In such cases splenectomy alone is adequate for localized disease when negative for IGH/BCL2 fusion regardless of histological grade.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • ITGAE (Integrin Subunit Alpha E) • ITGAX (Integrin Subunit Alpha X)
    |
    BCL2 fusion
    over1year
    EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16. (PubMed, Leuk Lymphoma)
    These results suggest that DZNep may have potential as a novel therapeutic agent for DFLBL therapy. This agent may serve as a novel molecular agent to be applied to GCB DLBCL.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • CD79B (CD79b Molecule) • NOTCH2 (Notch 2)
    |
    NOTCH1 mutation • EZH2 mutation • MYD88 L265P • NOTCH2 mutation • BCL2 fusion • BCL6 fusion
    over1year
    Follicular Lymphoma of the Oral Mucosa: Study of 5 Cases and Review of Literature (CAP 2022)
    Follicular lymphoma is a rare extranodal NHL of the oral cavity, compared with variants of NHL. Although FLs share similar morphologic and immunohistochemical features, they can reveal some molecular and genetic differences.
    Clinical • Review
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SPN (Sialophorin)
    |
    BCL6 rearrangement • BCL2 rearrangement • BCL2 fusion
    over1year
    Follicular Lymphoma of the Oral Mucosa: Study of 5 Cases and Review of Literature (CAP 2022)
    Follicular lymphoma is a rare extranodal NHL of the oral cavity, compared with variants of NHL. Although FLs share similar morphologic and immunohistochemical features, they can reveal some molecular and genetic differences.
    Clinical • Review
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SPN (Sialophorin)
    |
    BCL6 rearrangement • BCL2 rearrangement • BCL2 fusion
    over2years
    [VIRTUAL] Unusual Presentation of Cyclin D1 Expression in a Case of Follicular Lymphoma That Transformed to an Epstein-Barr Virus (EBV)–Positive Diffuse Large B-Cell Lymphoma (CAP 2021)
    The presence of trisomy 11 in a subset of cells may explain the partial cyclin D1 overexpression observed. To avoid an incorrect diagnosis when cyclin D1 expression is observed in part of the lymphoma cells, FISH analysis is critical.
    Clinical • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive • CCND1 overexpression • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement • BCL2 fusion
    3years
    [VIRTUAL] Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification. (ASCO 2021)
    Several rare and novel fusions were identified; a sarcoma with TPM4-NTRK3 fusion responded to larotrectinib, while a sarcoma with PML-JAK1 fusion did not respond to ruxolitinib, and a sarcoma with IL7R-BCL2 fusion progressed on venetoclax . NGS profiling led to a targeted therapy with a clinical benefit rate of 12% in this cohort . NGS profiling led to a change in diagnosis in 5% of this cohort . Multi-institutional collaborations to track outcomes of matched therapy would help determine the utility of therapies in rare cancers and unusual alterations.
    Clinical • Next-generation sequencing • Tumor Mutational Burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • TPM4 (Tropomyosin 4)
    |
    TMB-H • NTRK3 fusion • MET amplification • IL7R-BCL2 fusion • PML-JAK1 fusion • TPM4-NTRK3 fusion • BCL2 fusion
    |
    Venclexta (venetoclax) • Xalkori (crizotinib) • Vitrakvi (larotrectinib) • Jakafi (ruxolitinib)
    3years
    Newly diagnosed follicular lymphoma during pembrolizumab treatment for lung cancer. (PubMed, Int J Hematol)
    Malignant lymphoma developing during anti-PD-1 antibody treatment is extremely rare. Relapsed FL was diagnosed by submandibular gland biopsy four months after restarting PEM and she achieved a second CMR after rituximab-containing chemotherapy. We describe the first case of newly diagnosed FL during PEM treatment.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • IL2 (Interleukin 2)
    |
    BCL2 fusion
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab)